Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Jasper Therapeutics (JSPR) completed enrollment in the IgA nephropathy portion of its Phase 2 renal basket study evaluating vensobafusp alfa (KP104). Stage 1 enrolled 18 patients across three dosing cohorts, each with six patients receiving an induction regimen followed by subcutaneous maintenance dosing every two, four or eight weeks. This stage assesses safety, tolerability and initial efficacy to help determine doses for further evaluation.
Jasper expects initial interim IgA nephropathy data by year-end 2026. It has accelerated initiation of an additional cohort for focal segmental glomerulosclerosis, with first-patient dosing anticipated in the first quarter of 2027. The study is conducted in China and also covers complement 3 glomerulopathy. Jasper is exploring further cohorts in other complement-mediated kidney diseases.
Jasper Therapeutics (JSPR) commenced an offer to purchase all outstanding warrants issued in its September 2025 offering for $0.324 each in cash. There were 12,345,707 warrants outstanding as of October 6, 2026. Jasper expects to pay approximately $4.0 million from cash on hand if all are tendered.
The company aims to reduce potential dilution by retiring and cancelling tendered warrants. Each warrant permits purchase of one common share at $2.92, subject to adjustment. The offer expires one minute after 11:59 p.m. Eastern Time on November 6, 2026, unless extended or terminated earlier. No minimum tender is required. Holders may tender any number and withdraw before expiration; untendered warrants retain their original terms.
Jasper Therapeutics (JSPR) appointed Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs, and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development following its merger with Kira Pharmaceuticals. The company said their regulatory and clinical expertise will support development of vensobafusp alfa (KP104), briquilimab and KP701 in immune-mediated diseases.
Pitt brings over 25 years of regulatory and medical affairs experience across industry and the U.S. Food and Drug Administration, including leadership roles at Aiolos Bio, NorthSea Therapeutics, Horizon Therapeutics, Viela Bio, AstraZeneca, PAREXEL and Novartis. Liu joins after more than a decade at Sanofi in research and development, pharmacovigilance and clinical development, with a focus on rare renal and metabolic diseases and late-stage trials.
On September 14, 2026, Jasper also granted three new employees stock options for an aggregate 243,000 shares at an exercise price of $0.6328 per share as material inducement grants under its 2022 Inducement Equity Incentive Plan. The options vest over four years, with 25% after one year and the remainder monthly, subject to continued service.
Jasper Therapeutics (JSPR) will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York, NY.
The company’s fireside chat is scheduled for Wednesday, September 16, 2026 at 8:00 AM ET. A live webcast and a 30-day archived replay will be available via the News & Events – Events section of Jasper’s Investor Relations website.
Jasper Therapeutics (Nasdaq:JSPR) reported second quarter 2026 results and detailed its post‑merger strategy following completion of the all‑stock acquisition of Kira Pharmaceuticals on July 16, 2026. Concurrently, Jasper closed a PIPE financing of non‑voting convertible preferred stock, generating approximately $132 million in gross proceeds, which the company believes will fund planned operations into the second half of 2028.
The combined company is advancing three key clinical assets: KP‑104, a Phase 2 basket trial in rare renal indications with interim data expected in Q4 2026; briquilimab, moving toward a pre‑BLA meeting with the FDA with next‑step guidance expected in Q1 2027; and KP‑701, for which a Phase 1 CTA/IND filing is targeted for Q1 2027. As of June 30, 2026, cash and cash equivalents were $7.3 million. Q2 2026 research and development expense was $5.1 million and general and administrative expense was $4.1 million, resulting in a net loss of $2.8 million, or $0.10 per basic and diluted share, compared with a net loss of $26.7 million, or $1.74 per share, in Q2 2025.
Jasper Therapeutics (Nasdaq: JSPR) has completed an all-stock acquisition of Kira Pharmaceuticals, creating a combined company focused on biologic therapies for immunologically-driven disorders. Concurrently, Jasper entered a private placement of non-voting convertible preferred stock expected to raise approximately $132 million, led by specialist life sciences investors, to fund the consolidated pipeline.
The portfolio centers on KP-104 for paroxysmal nocturnal hemoglobinuria and rare renal disorders, briquilimab for transplant and immunologic indications including SCID, and preclinical KP-701 for autoantibody-mediated diseases. Kira also out-licensed KP-301 and KP-402 to Mirador Therapeutics for a $12 million upfront payment plus potential milestones. According to Jasper Therapeutics, pro-forma cash, including the placement and out-licensing proceeds, is expected to fund operations and multiple clinical milestones through the second half of 2028, while the combined company continues to trade under the ticker JSPR.
Jasper Therapeutics (Nasdaq:JSPR) announced that its board has begun a comprehensive review of strategic alternatives to maximize shareholder value after assessing current market conditions.
Options include asset sales or licenses, collaborations, a company sale, business combination or merger, or an orderly wind-down, while continuing cost-saving efforts and regulatory compliance.
Jasper Therapeutics (Nasdaq:JSPR) reported first quarter 2026 results and a briquilimab clinical update. The company focuses on mast cell driven diseases such as chronic spontaneous urticaria (CSU) and asthma.
Jasper refiled a Phase 2b CSU protocol with the FDA, highlighted positive briquilimab data, held $14.1 million in cash and cash equivalents, and reported a net loss of $1.2 million for Q1 2026.
Jasper Therapeutics (Nasdaq: JSPR) reported Q4 and full-year 2025 results and clinical updates on briquilimab, an anti‑c‑Kit antibody for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. Key clinical signals: positive BEACON and open‑label extension CSU data, ETESIAN asthma proof‑of‑concept, dose selection for Phase 2b planned H2 2026. Financials: cash of $28.7M at Dec 31, 2025 and a 2025 net loss of $75.8M. Company noted Phase 2b enrollment timing is pending capital availability.
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, March 2-4, 2026.
The company will participate in a Fireside Chat on Monday, March 2, 2026 at 3:50 PM ET. According to the company, a live webcast will be available on its investor website and an archived replay will remain online for 30 days.